![Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial - The Lancet Oncology Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3edb0cce-c7c5-4ea2-8242-318b3124acf1/gr1.gif)
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial - The Lancet Oncology
![A trial of additional treatment for oesophageal cancer and stomach cancer (PLATFORM) | Cancer Research UK A trial of additional treatment for oesophageal cancer and stomach cancer (PLATFORM) | Cancer Research UK](https://www.cancerresearchuk.org/sites/default/files/styles/cruk_wide_resp_breakpoint_one/public/11683-for-web_1.png?itok=oFyWxZR0)
A trial of additional treatment for oesophageal cancer and stomach cancer (PLATFORM) | Cancer Research UK
![Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2b056e18-83a9-490f-affa-8bfa8d8064b7/gr1.jpg)
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
![Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial - The Lancet Gastroenterology & Hepatology Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/b2a993e0-75e6-4fe3-b84d-2356647b0a4b/gr1.jpg)
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial - The Lancet Gastroenterology & Hepatology
![The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 - The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d04b085e-159f-40c7-ac5c-b2185b182b30/gr1.jpg)
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 -
![Immune boosting antibody trialled in patients with oesophageal cancer | Southampton Clinical Trials Unit | University of Southampton Immune boosting antibody trialled in patients with oesophageal cancer | Southampton Clinical Trials Unit | University of Southampton](https://cdn.southampton.ac.uk/img/ctu/Elevate%20logo%20(resized).jpg?csf=1&web=1&e=dTEB7V)
Immune boosting antibody trialled in patients with oesophageal cancer | Southampton Clinical Trials Unit | University of Southampton
![A trial looking at improving chemoradiotherapy for people with cancer of the food pipe (SCOPE 2) | Cancer Research UK A trial looking at improving chemoradiotherapy for people with cancer of the food pipe (SCOPE 2) | Cancer Research UK](https://www.cancerresearchuk.org/sites/default/files/styles/cruk_wide_resp_breakpoint_one/public/diagram_showing_scope2_randomisation.png?itok=5p1Yz7ys)
A trial looking at improving chemoradiotherapy for people with cancer of the food pipe (SCOPE 2) | Cancer Research UK
![Frontiers | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2 ... Frontiers | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2 ...](https://www.frontiersin.org/files/Articles/496507/fonc-09-01320-HTML/image_m/fonc-09-01320-g001.jpg)
Frontiers | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2 ...
![Cancers | Free Full-Text | The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview Cancers | Free Full-Text | The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview](https://www.mdpi.com/cancers/cancers-12-02567/article_deploy/html/images/cancers-12-02567-g001.png)
Cancers | Free Full-Text | The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
![Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study) - eClinicalMedicine Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/585dca4a-fa26-43de-8a01-f4e85c252169/gr1_lrg.jpg)
Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study) - eClinicalMedicine
![Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka](https://cyberleninka.org/viewer_images/272989/f/1.png)
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka
![New option to treat advanced oesophageal cancer approved for NHS in Scotland - Cancer Research UK - Cancer news New option to treat advanced oesophageal cancer approved for NHS in Scotland - Cancer Research UK - Cancer news](https://news.cancerresearchuk.org/wp-content/uploads/2021/08/oesophageal-cancer_hero.jpg)